At the American Society for Radiation Oncology annual meeting, phase 3 clinical results were announced: SBRT radiotherapy for localized prostate cancer achieves long-term control rates comparable to radical prostatectomy and greatly reduces the risk of incontinence.

A latest phase 3 randomized controlled clinical study announced at the American Society for Radiation Oncology (ASTRO) annual meeting shows that for patients with localized prostate cancer (PCa), stereotactic body radiotherapy (SBRT) demonstrates excellent clinical application potential. Follow-up data show that SBRT is comparable to traditional radical prostatectomy in 8-year biochemical or clinical failure-free rates, and the incidence of urinary incontinence at 5 years after treatment is significantly reduced by nearly 40%. This phase 3 multicenter clinical trial...

2026-09-30

Chest CT Can Measure Bone Density and Warn of Brain Aging Risk: Latest Research Reveals Link Between Skeletal and Cognitive Decline

Chest computed tomography (CT), routinely used to screen for lung lesions, may hold important clues for assessing brain health. A research team from Johns Hopkins University in the United States explored approaches to using existing chest imaging to assess bone health and link it to brain aging, with the related findings published in September 2026 in the authoritative journal Radiology. The study showed that subjects with lower thoracic vertebral bone density experienced faster cognitive decline during subsequent follow-up, and specific white matter microstructural changes also showed associated degeneration. Chest CT is widely used in lung cancer screening and pulmonary nodule follow-up...

2026-09-30

China Institute of Atomic Energy Holds Advanced Scientific and Technological Achievements Transformation Conference: Releases Small Reactor 9-Type Product Matrix, Signs Agreements on Curie-Level Terbium-161 Preparation and SMR Overall Scheme Design

On September 29, the China Institute of Atomic Energy (abbreviated as CIAE) held in Beijing an Advanced Scientific and Technological Achievements Transformation Conference themed "Innovation · Nuclear Fusion of New Quality." The conference showcased CIAE's practical breakthroughs in deepening scientific and technological system reform, advancing the pilot program for empowering scientific and technological achievements from job-related inventions, and integrated institute-enterprise operations, and officially released multiple major scientific research achievements covering advanced reactors, nuclear medical equipment, and isotope preparation, vigorously promoting the acceleration of nuclear technology from the laboratory to the production line. In the report on reform experience and benchmark incubation platforms, the conference systematically summarized three landmark reform achievements: SASAC Pilot Reform for Empowering Scientific and Technological Achievements from Job-Related Inventions: CIAE used...

2026-09-30

Civil Construction of Huizhou Heavy Ion Medical Center Passes Completion Acceptance and Transitions to Accelerator No-Load Commissioning

Recently, according to public information from the Huizhou Municipal Health Bureau, all approval procedures for the Heavy Ion Medical Center project of Huizhou Municipal Central Hospital have been completed, civil construction is 99.6% complete and has passed completion acceptance, and internal decoration and accelerator no-load commissioning are currently underway; the accelerator equipment investment is 480 million yuan, of which 303 million yuan has been disbursed. The project is planned to launch clinical trials in March 2027 and be officially put into operation by the end of the year. The center is adjacent to the Jinshan Campus of Huizhou Municipal Central Hospital, with a land area of approximately 12,000 square meters and a total floor area of 15,450 square meters; all heavy ion treatment rooms are located underground; 150 supporting inpatient beds are planned, with 2 treatment rooms to be opened initially, capable of treating approximately 900 cancer patients per year. The center...

2026-09-30

Rosatom RDS presented domestic high-end medical equipment in Perm to accelerate regional healthcare import substitution

On September 25, 2026, the Second International Conference "Bioethics – A Panoramic View of the Future" (Биоэтика – панорамный взгляд в будущее) successfully concluded in Perm, Russia. Rosatom RDS JSC (АО «Росатом РДС»), the industry integration platform under the Russian State Atomic Energy Corporation (Rosatom) responsible for instruments and electronic equipment manufacturing, participated deeply in this event. During the special seminar on "Ethical Considerations of the Peaceful Use of Atomic Energy in Medicine" held as part of the conference, Rosatom RDS representatives...

2026-09-27

Miniature "Plug-and-Play" Platform Poised to Accelerate Development of New PET Radiotracers

A research team at the Keck School of Medicine of USC is working to develop a miniature plug-and-play chip platform aimed at significantly accelerating the synthesis and preparation of novel positron emission tomography (PET) radiotracers. The project aims to lower the barriers and costs of developing molecular imaging probes, and has received a four-year, $2.6 million research grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the National Institutes of Health (NIH). The project is led by Dr. Kai Chen, PhD, professor of radiology, radiation oncology, and pharmacology and pharmaceutical sciences at USC...

2026-09-27

FDA Approves Lantheus' Bravnetsa for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors

The U.S. Food and Drug Administration (FDA) has formally approved Lantheus Holdings' radioligand therapy drug Bravnetsa (lutetium Lu 177 dotatate injection) for the treatment of somatostatin receptor-positive adult gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The approved indication covers neuroendocrine tumors originating from the foregut, midgut, and hindgut. Following FDA review, Bravnetsa has been determined to be bioequivalent and therapeutically equivalent to Novartis'...

2026-09-27

Sichuan Advances Cluster-Based Breakthroughs in Nuclear Medicine, Leveraging "One Chain, Four Poles" to Accelerate Clinical Translation and Deployment

At the 2026 Nuclear Technology Application and Nuclear Medicine Industry Innovation Development Conference held in Mianyang, Sichuan, participants focused on the strategic emerging industry track of deep integration between nuclear technology and modern medicine. As a key vehicle for developing new quality productive forces, Sichuan's nuclear medicine industry, relying on its long-accumulated advantages in scientific research and reactor irradiation resources, continues to expand in scale; according to the China Isotope & Radiation Association, Sichuan's nuclear medicine output value is projected to surpass the 10 billion yuan mark in 2026. In the fields of basic raw materials and therapeutic equipment, Sichuan possesses outstanding advantages in resource security and manufacturing concentration. More than 80% of the nation's medical isotopes rely on reactor irradiation for production, and the relevant reactors currently owned by Sichuan...

2026-09-24

Miniaturized Plug-and-Play Platform R&D Accelerates, Poised to Revolutionize Novel Positron Emission Tomography Radiotracer Preparation Workflow

A research team at the Keck School of Medicine of USC is developing a miniaturized plug-and-play microfluidic platform aimed at significantly accelerating the synthesis and R&D cycle of novel positron emission tomography (PET) radiotracers. The project has received a four-year, $2.6 million dedicated research...

2026-09-24

CNNC High Energy Seminar Focuses on Quality Control of Domestic Radiotherapy Equipment, Multiple Parties Join Hands to Build Industry Standards

On September 21, in order to further promote the construction of a quality control system for domestic radiotherapy equipment, standardize clinical quality control work for Tomo equipment, and facilitate multi-party collaborative development among industry, academia, research, and medical institutions, CNNC High Energy organized a seminar on quality control standardization for radiotherapy equipment. The meeting brought together industry forces from multiple sectors. Professor Zhang Fuquan, President of the Radiotherapy Equipment Technology Branch of the China Association of Medical Equipment and of Peking Union Medical College Hospital, and Professor Qiu Jie, Vice President of the Radiotherapy Equipment Technology Branch of the China Association of Medical Equipment and of Peking Union Medical College Hospital, attended the meeting as clinical experts; management, technical, and business representatives from CNNC High Energy, CNNC Accuray, Shuimu Medical, Shuimu Lingrui, and other units attended the meeting together. At the meeting, with...

2026-09-22

Guoke Ion Makes Its Debut at AOCMP 2026, Domestic Ion Therapy Technology Draws Attention from Asia-Pacific Peers

From September 9 to 11, 2026, the 26th Asia-Oceania Congress of Medical Physics (AOCMP 2026) was held at the Busan Port International Exhibition & Convention Center (BPEX) in South Korea. Hosted by the Korean Society of Medical Physics (KSMP), this year's congress focused on innovative applications of cutting-edge technologies such as artificial intelligence and automation in the field of medical physics, and is a highly influential academic event in the Asia-Pacific region. Wang Xiaomin, Deputy General Manager of Guoke Ion, and Yang Wenjie, Assistant to the General Manager, led a delegation to attend the congress, actively carrying out academic exchanges and industry engagement. During the congress, the Guoke Ion team conducted technical presentations and exchanges through specialized seminars and a corporate exhibition booth. At the specialized seminar, the team systematically introduced the company's ion therapy equipment and its self-developed...

2026-09-22

CGN and the People's Government of Sichuan Province Sign a Strategic Cooperation Agreement

On September 21, China General Nuclear Power Group Co., Ltd. and the People's Government of Sichuan Province signed a strategic cooperation agreement in Chengdu. Wang Xiaohui, Secretary of the Sichuan Provincial Party Committee and Director of the Standing Committee of the Sichuan Provincial People's Congress, Shi Xiaolin, Deputy Secretary of the Provincial Party Committee and Governor, held a working meeting with Yang Changli, Secretary of the Party Committee and Chairman of China General Nuclear Power Group Co., Ltd., and Pang Songtao, Deputy Secretary of the Party Committee and General Manager, and together witnessed the signing of the agreement. During the meeting, the two sides, focusing on implementing General Secretary Xi Jinping's important instructions on Sichuan's work and the decisions and arrangements of the Party Central Committee, exchanged views on deepening strategic cooperation during the 15th Five-Year Plan period, further optimizing the investment layout in Sichuan, promoting clean energy development and construction, strengthening the high-end energy equipment manufacturing industry, and advancing...

2026-09-22

Jiluntai's independently developed HER2-targeted diagnostic new drug has been approved for clinical trials, expected to facilitate precision treatment of breast cancer

Jiluntai Company, a nuclear medicine innovation enterprise invested and incubated by Baiyang Pharmaceutical Group, has recently made important progress. Its independently developed Class 1 chemical radioactive diagnostic new drug —— Technetium [⁹⁹ᵐTc] hydrazinonicotinamide dual-chain Ark peptide injection (⁹⁹ᵐTc‑HP‑Ark2), has received supplementary clinical trial application approval from the National Medical Products Administration (NMPA), which means the product will continue to undergo clinical trials, bringing new hope for precision subtyping and treatment of breast cancer. This product is a radioactive diagnostic agent for SPECT/CT imaging, intended for the differential diagnosis of HER2-positive breast cancer. HER2 is an important prognostic indicator for malignant tumors such as breast cancer...

2026-09-21

Microstructure Imaging's MICSI-PET Software Receives FDA Clearance to Enhance Neurological PET Imaging Using MRI

Microstructure Imaging's software platform has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The platform is designed to enhance neurological positron emission tomography (PET) images using structural magnetic resonance imaging (MRI). The software, called MICSI-PET, can denoise and super-resolve PET images using MRI guidance while preserving quantitative PET information. It supports PET exams for amyloid, Tau, and FDG (fluorodeoxyglucose), and can provide automated Centiloid measurements for amyloid imaging and CenTauR measurements for Tau imaging....

2026-09-18

Oman Reaffirms Cooperation Commitment at IAEA General Conference, Promotes Peaceful Uses of Nuclear Technology

The Sultanate of Oman delivered a statement at the 70th Regular Session of the International Atomic Energy Agency (IAEA) General Conference held in Vienna, Austria, expressing appreciation for the work of the IAEA Secretariat and reaffirming its continued close cooperation with the Agency and its Member States to achieve strategic objectives and further enhance the key role of nuclear technology in peace and modern development. The statement was delivered on behalf of the Sultanate of Oman by Faiza Saif Al Siyabi, Chargé d'Affaires of Oman's Permanent Mission to the IAEA. In its statement, Oman welcomed the Democratic Republic of Timor-Leste as a new member of the IAEA. Oman emphasized in its statement its active participation...

2026-09-17

ZAP-X Gyroscopic Stereotactic Radiosurgery Platform Makes Its Australian Debut, Expanding Precision Non-Invasive Brain Radiotherapy

ZAP Surgical, the global leader in non-invasive robotic brain surgery, recently announced that GenesisCare will become the first cancer care provider in Australia to introduce the ZAP-X Gyroscopic Radiosurgery platform. Installation of the device is scheduled to begin this month at the GenesisCare center located at St Vincent's Hospital Sydney in New South Wales, with the first patients expected to receive treatment before the end of this year. The introduction of the ZAP-X platform will significantly enhance GenesisCare's neuro-oncology diagnostic and treatment capabilities in Sydney, providing it with dedicated stereotactic radiosurgery (SRS) services. Prior to this, patients receiving S...

2026-09-17

FDA Grants 510(k) Clearance to Emboliner System for TAVR Procedures

The U.S. Food and Drug Administration (FDA) has approved Emboliner, a cardiac protection system from Emboline, for percutaneous coronary intervention (TAVR) and other cardiac procedures. The device is designed to capture and remove embolic material generated during TAVR, protecting vital organs such as the brain and kidneys. The Emboliner system uses a dual-layer annular filter to cover the brain and systemic arteries, designed to intercept and clear debris generated during TAVR procedures. Unlike other embolic protection devices that only shield selected cerebral vessels, this design allows the central lumen of the TAVR delivery system to pass through the filter, effectively enhancing the scope of protection. The FDA's decision follows a comprehensive clinical evaluation of Embol...

2026-09-17

Hyperfine Completes Patient Enrollment in Contrast-Enhanced MRI (Contrast PMR) Study of Swoop MRI System

Hyperfine announced that it has completed patient enrollment in its contrast-enhanced PMR study, which is designed to evaluate the potential of the company's portable Swoop MRI system to use gadolinium-based contrast agents. The study will investigate the contrast-enhancement capability of ultra-low-field magnetic resonance imaging to improve visualization of brain lesions. Hyperfine plans to use the study data to support the first expanded indication application for the Swoop system since it initially received FDA clearance. The focus of this study is on how the Swoop system can use gadolinium-based contrast agents to visualize lesions associated with blood-brain barrier disruption, such as those observed in brain tumors and inflammatory diseases. The study's...

2026-09-17

Curium's Lutetium-177 Injection Approved by FDA for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Radiopharmaceutical company Curium recently announced that its developed lutetium-177 (Lu-177) dotatate injection (trade name: Bexlutry) has received formal approval from the U.S. Food and Drug Administration (FDA). The drug is indicated for the treatment of somatostatin receptor-positive adult gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The specific indication scope includes various neuroendocrine tumors occurring in the adult foregut, midgut, and hindgut. Bexlutry is an advanced radioligand therapy whose mechanism of action lies in its ability to specifically bind to somatostatin receptors highly expressed on the surface of such tumors. Through this precise binding, the drug can deliver...

2026-09-16

DeVry University and Pulse Radiology Institute Partner to Launch Degree in Magnetic Resonance Imaging Technology

DeVry University and Pulse Radiology Institute (Pulse Radiology Institute) recently announced a partnership to jointly launch a new associate degree specialization in Magnetic Resonance Imaging (MRI) technology. This degree program innovatively combines DeVry University's flexible and convenient online theoretical courses with Pulse Radiology Institute's mature clinical training model and its network of college and healthcare partners across the United States. The core purpose of launching this hybrid training program is to address the staffing shortage crisis currently facing the healthcare industry. According to data published by the American Society of Radiologic Technologists (ASRT), the current vacancy rate for MRI technologists is as high as 1...

2026-09-16

IAEA's Rays of Hope Initiative Boosts Global Cancer Care

The IAEA's Rays of Hope initiative aims to expand access to cancer care, drive innovation, and build partnerships to narrow the global gap in cancer treatment. Every year, cancer claims more than 10 million lives, and that number is expected to nearly double by 2050. While many cancers are treatable, especially when detected early, timely diagnosis and life-saving treatment are unevenly distributed around the world. Low- and middle-income countries often lack modern medical imaging and radiotherapy equipment, trained oncologists, research capacity, and basic services. More than half of cancer cases occur in these countries, and nearly two-thirds...

2026-09-16